Published in Antimicrob Agents Chemother on March 01, 2000
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci U S A (2001) 2.49
HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model. Retrovirology (2006) 2.17
Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. PLoS One (2007) 1.40
Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS One (2007) 1.06
Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J Biol Chem (2008) 1.05
Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque. Antimicrob Agents Chemother (2015) 0.88
Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice. J Virol (2001) 0.81
Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection. Chem Biol (2015) 0.80
Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice. Virology (2014) 0.78
Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy/Liv mice. Antimicrob Agents Chemother (2012) 0.77
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science (1988) 9.05
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A (1993) 6.14
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother (1993) 5.08
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis (1995) 4.60
Infection of the SCID-hu mouse by HIV-1. Science (1988) 4.37
HIV induces thymus depletion in vivo. Nature (1993) 3.73
Long-term human hematopoiesis in the SCID-hu mouse. J Exp Med (1990) 3.59
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 3.57
The SCID-hu mouse as a model for HIV-1 infection. Nature (1993) 3.43
Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. J Exp Med (1993) 2.81
HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo. Immunity (1995) 2.07
CXCR4 expression during lymphopoiesis: implications for human immunodeficiency virus type 1 infection of the thymus. J Virol (1997) 1.88
Rapid-high, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse. J Virol (1994) 1.87
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis (1999) 1.75
CCR5- and CXCR4-utilizing strains of human immunodeficiency virus type 1 exhibit differential tropism and pathogenesis in vivo. J Virol (1998) 1.72
Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS (1995) 1.58
Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds. Antimicrob Agents Chemother (1996) 1.54
Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob Agents Chemother (1996) 1.51
Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine. Antiviral Res (1995) 1.26
Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. Antimicrob Agents Chemother (1999) 1.11
Regions of human immunodeficiency virus type 1 nef required for function in vivo. J Virol (1998) 1.09
Animal models of HIV-1 disease. Science (1997) 1.04
Identification of HIV-1 determinants for replication in vivo. Virology (1997) 1.02
Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro. J Med Chem (1995) 1.01
3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. J Virol (1998) 0.92
Inhibition of human immunodeficiency virus type 1 infection in SCID-hu Thy/Liv mice by the G-quartet-forming oligonucleotide, ISIS 5320. Antimicrob Agents Chemother (1998) 0.85
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med (2001) 5.33
Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med (1999) 4.74
Infection of the SCID-hu mouse by HIV-1. Science (1988) 4.37
Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods (2001) 4.25
HIV induces thymus depletion in vivo. Nature (1993) 3.73
Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med (2001) 3.69
Long-term human hematopoiesis in the SCID-hu mouse. J Exp Med (1990) 3.59
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother (1997) 2.98
Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. J Exp Med (1993) 2.81
HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant (2007) 2.50
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci U S A (2001) 2.49
Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS (2001) 2.47
Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA. Proc Natl Acad Sci U S A (2002) 2.46
Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med (1998) 2.27
Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res (2001) 2.17
Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science (1995) 2.16
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med (2001) 2.13
Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles. J Med Chem (1997) 2.08
HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo. Immunity (1995) 2.07
Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell (2000) 2.02
Ion channels in plasmalemma of wheat protoplasts. Science (1984) 1.98
Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci U S A (1994) 1.94
The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem (1992) 1.89
Potassium Channels in Motor Cells of Samanea saman: A Patch-Clamp Study. Plant Physiol (1988) 1.88
Rapid-high, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse. J Virol (1994) 1.87
Isolation and immunologic characterization of a human. B-lymphocyte-specific, cell surface antigen. J Exp Med (1976) 1.74
CCR5- and CXCR4-utilizing strains of human immunodeficiency virus type 1 exhibit differential tropism and pathogenesis in vivo. J Virol (1998) 1.72
IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood (2001) 1.72
Human cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication. Proc Natl Acad Sci U S A (1993) 1.70
Direct evidence for thymic function in adult humans. J Exp Med (1999) 1.70
Human T cells in the SCID-hu mouse are phenotypically normal and functionally competent. J Immunol (1991) 1.65
CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T cell differentiation. J Immunol (1998) 1.64
Measles virus infection of thymic epithelium in the SCID-hu mouse leads to thymocyte apoptosis. J Virol (1996) 1.61
Experimental transmission of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) to SCID-hu Thy/Liv mice. J Exp Med (1999) 1.61
Inherited congenital normofunctional testicular hyperplasia and mental deficiency. A corroborative study. Hum Genet (1978) 1.56
Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds. Antimicrob Agents Chemother (1996) 1.54
A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res (1991) 1.51
Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob Agents Chemother (1996) 1.51
Two types of Ia-positive T cells. Synthesis and exchange of Ia antigens. J Exp Med (1980) 1.47
Real-time quantitative PCR for human herpesvirus 6 DNA. J Clin Microbiol (2000) 1.44
Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis (2000) 1.43
Is determination of the hepatic iron index of diagnostic value in patients with thalassemia minor and chronic alcoholic liver disease? Hepatology (1991) 1.38
Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element. Nucleic Acids Res (1991) 1.37
T cell turnover in HIV-1 disease. Immunity (1997) 1.35
Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis. J Infect Dis (2001) 1.32
Isolation and characterization of a novel human papillomavirus type 6 DNA from an invasive vulvar carcinoma. J Virol (1986) 1.32
Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood (1992) 1.31
Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 1.30
Pre-B cells and other possible precursor lymphoid cell lines derived from patients with X-linked agammaglobulinemia. J Exp Med (1980) 1.28
Inherited congenital normofunctional testicular hyperplasia and mental deficiency. Hum Genet (1976) 1.27
Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob Agents Chemother (1999) 1.26
Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Res (1997) 1.26
Clonal analysis of the peripheral T cell compartment of the SCID-hu mouse. J Immunol (1991) 1.26
Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol Pharmacol (1998) 1.25
Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol (1992) 1.24
Ion selective folding of loop domains in a potent anti-HIV oligonucleotide. Biochemistry (1997) 1.23
Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects. Virology (2001) 1.23
Biogenesis of membrane-bound and secreted immunoglobulins. I. Two distinct translation products of human mu-chain, with identical N-termini and different C-termini. J Exp Med (1980) 1.21
Human immunodeficiency virus infection of human lymph nodes in the SCID-hu mouse. Proc Natl Acad Sci U S A (1991) 1.21
Mechanism for human papillomavirus transmission at birth. Am J Obstet Gynecol (1989) 1.20
Enhanced representation of HL-A antigens on human lymphocytes after mitogenesis induced by phytohemagglutinin or Epstein-Barr virus. Proc Natl Acad Sci U S A (1975) 1.20
Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. Biochem Pharmacol (1996) 1.20
Antiviral properties of a series of 1,6-naphthyridine and 7, 8-dihydroisoquinoline derivatives exhibiting potent activity against human cytomegalovirus. Antimicrob Agents Chemother (2000) 1.20
Analysis of the 16S rRNA gene sequence of the coryneform bacterium associated with hyperkeratotic dermatitis of athymic nude mice and development of a PCR-based detection assay. Mol Cell Probes (1998) 1.16
Lymphoid reconstitution of the human fetal thymus in SCID mice with CD34+ precursor cells. J Exp Med (1991) 1.16
Design and synthesis of monocyclic beta-lactams as mechanism-based inhibitors of human cytomegalovirus protease. Bioorg Med Chem Lett (1998) 1.16
Outbreaks of hyperkeratotic dermatitis of athymic nude mice in northern Italy. Lab Anim (1997) 1.16
Potassium-induced loop conformational transition of a potent anti-HIV oligonucleotide. J Biomol Struct Dyn (1997) 1.16
Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Mol Pharmacol (1997) 1.15
Human immunodeficiency virus-1 infection interrupts thymopoiesis and multilineage hematopoiesis in vivo. Blood (1998) 1.14
Reversal of human immunodeficiency virus type 1-associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis (2000) 1.14
[3 cases of sodium azide poisoning]. Med Lav (1967) 1.14
Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry (1996) 1.13
Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Antivir Chem Chemother (1999) 1.13
The noncoding region of HPV-6vc contains two distinct transcriptional enhancing elements. Virology (1986) 1.12
T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1995) 1.11
Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. Antimicrob Agents Chemother (1999) 1.11
J chain biosynthesis in pre-B cells and other possible precursor B cells. J Exp Med (1981) 1.10
Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. J Biol Chem (1996) 1.08
Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J Infect Dis (1991) 1.07
Human herpesvirus 6 (HHV-6) causes severe thymocyte depletion in SCID-hu Thy/Liv mice. J Exp Med (1999) 1.06
Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors. J Med Chem (1996) 1.05
Reciprocal enhancement of gene expression and viral replication between human cytomegalovirus and human immunodeficiency virus type 1. J Gen Virol (1990) 1.05
Impermeability to quinolones in gram-positive and gram-negative bacteria. Eur J Clin Microbiol Infect Dis (1991) 1.04
Hyperkeratosis-associated coryneform infection in severe combined immunodeficient mice. Lab Anim (1998) 1.04
Induction of MHC class I expression on immature thymocytes in HIV-1-infected SCID-hu Thy/Liv mice: evidence of indirect mechanisms. J Immunol (1999) 1.03
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors. J Med Chem (1999) 1.01
Development of a human thymic organ culture model for the study of HIV pathogenesis. AIDS Res Hum Retroviruses (1995) 1.00
Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor. Antiviral Res (1996) 1.00
Suppression of T-cell responsiveness by inducible cAMP early repressor (ICER). J Leukoc Biol (2001) 1.00